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The compound 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD or dioxin) is the most
toxic member of a class of planar, halo-
genated aromatic hydrocarbons (1,2).
TCDD is a widespread environmental cont-
aminant produced by various chemical reac-
tions and combustion processes (3). It is
highly lipophilic and extremely stable and
thus accumulates in the food chain (2).
TCDD has a half-life of 7–9 years in
humans (4). In animals, TCDD is a potent
carcinogen and has been shown to disrupt
multiple endocrine pathways (1,2,5). The
International Agency for Research on
Cancer has classified TCDD as a known
human carcinogen, primarily on the basis of
occupational studies of increased mortality
from all cancers combined, but no particular
cancer sites were predominant (5).
The few epidemiologic studies that have
examined the relationship between TCDD
exposure and breast cancer risk are limited by
small sample size and lack of individual expo-
sure data. Breast cancer mortality (6,7) and
incidence (8) increased in female workers
employed in the production of TCDD-cont-
aminated phenoxyherbicides. Significantly
increased mortality from breast cancer was
reported in a Russian town with a chemical
plant known to be a source of TCDD (9).
However, a hospital-based breast cancer
case–control study found no difference in
breast tissue concentration of TCDD between
women with breast cancer and women with
benign breast disease, but the level of exposure
was low (1.0–7.9 ppt, lipid-adjusted) (10). 
On 10 July 1976, an explosion at a
trichlorophenol manufacturing plant near
Seveso, Italy, resulted in the highest TCDD
levels known in human residential popula-
tions (11). Up to 30 kg of TCDD were
deposited over the surrounding area (~18
km2) (12), which was divided into exposure
zones (A, B, R, non-ABR) based on TCDD
measurements in soil. Ten- and 15-year fol-
low-up studies of the Seveso population
found no increased risk for breast cancer
incidence (13,14) or mortality (15–17).
However, after 20 years of follow-up, a statis-
tically nonsigniﬁcant increased risk for breast
cancer mortality emerged among women who
resided in zones A or B, the most heavily con-
taminated areas, and who were younger than
55 years at death [relative risk (RR) = 1.2,
95% conﬁdence interval (CI), 0.6–2.2], but
not in those who were older (18). Exposure
estimates were based on zone of residence, so
the study lacked individual-level exposure
data. Furthermore, recent analyses of individ-
ual serum TCDD measurements for 601
Seveso women suggest a wide range of indi-
vidual TCDD exposure within zones (19).
Using data from the Seveso Women’s
Health Study (SWHS) (20), a historical
cohort study of the female population resid-
ing around Seveso at the time of the explo-
sion in 1976, we examined the association
between breast cancer risk and individual-
level TCDD exposure, measured in archived
serum collected soon after the explosion (21).
Materials and Methods
Study population. Women eligible for the
SWHS were infants to 40 years old in 1976,
had resided in one of the most highly conta-
minated zones, A or B, and had adequate
stored sera collected soon after the explosion
(20). Enrollment began in March 1996 and
was completed in July 1998. Of 1,271 eligi-
ble women, 17 (1.3%) could not be located
or contacted, 21 (1.6%) had died, and 12
(1%) were too ill to participate. Of the
96.1% of eligible women who could be con-
tacted, 981 (80%) participated. 
Procedure. Details of the study proce-
dure are presented elsewhere (20). Briefly,
participation included obtaining informed
consent, drawing blood, and conducting
personal interviews and, for a subset of
women, a gynecologic examination and
transvaginal ultrasound. The interview was
conducted by a trained nurse-interviewer
who was blinded to serum TCDD levels and
zone of residence. At interview each woman
Address correspondence to M. Warner, School of
Public Health, University of California, 2150
Shattuck Avenue, Suite 600, Berkeley, CA 94720-
7380, USA. Telephone: (510) 642-9544. Fax: (510)
642-9083. E-mail: mwarner@uclink4.berkeley.edu
We gratefully acknowledge S. Casalini for coordi-
nating data collection at Hospital of Desio, W.
Turner (U.S. Centers for Disease Control and
Prevention) for serum TCDD measurements, and P.
Vercellini and D. Olive for comments on early drafts.
We especially thank the women of Seveso, Italy. 
This study was supported by grants R01 ES07171
and F06 TW02075-01 from the National Institutes
of Health, R82471 from the U.S. Environmental
Protection Agency, EA-M1977 from the
Endometriosis Association, 2P30-ESO01896-17
from the National Institute of Environmental
Health Sciences, and 2896 from Regione
Lombardia and Fondazione Lombardia Ambiente,
Milan, Italy.
Received 13 July 2001; accepted 17 December
2001.
Articles
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD or dioxin), a widespread environmental contami-
nant, has been shown to disrupt multiple endocrine pathways. The International Agency for
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hazard ratio for breast cancer associated with a 10-fold increase in serum TCDD levels (log10
TCDD) was signiﬁcantly increased to 2.1 (95% conﬁdence interval, 1.0–4.6). Covariate-adjusted
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with cancer. If she said yes, medical records
were obtained and were reviewed by a can-
cer pathologist who was blinded to the
woman’s exposure. This study was approved
by the Institutional Review Boards of the
participating institutions.
Laboratory analyses. For each partici-
pant, we selected the ﬁrst serum sample col-
lected between 1976 and 1981 of adequate
volume (> 0.5 mL) for analysis. We mea-
sured the TCDD concentration in these
samples, which had been stored at –20°C at
Desio Hospital, by high-resolution mass
spectrometry (22). Values were reported on
a lipid-weight basis in parts per trillion (23).
We measured TCDD in sera collected in
1976 or 1977 for 899 women (92%), from
1978 through 1981 for 54 women (5%),
and in 1996 or 1997 for 28 women (3%)
whose earlier samples had become concen-
trated by dessication. 
For four women whose post-1977
TCDD values were detectable but ≤ 10 ppt,
the measured value was used. For 42 women
whose post-1977 TCDD levels were > 10
ppt and who were more than 16 years old in
1976, the serum TCDD level was back-
extrapolated to 1976 using the first-order
kinetic model, assuming a 9-year half-life
(4). For 27 women whose post-1977 TCDD
levels were > 10 ppt, and who were 16 years
old or younger in 1976, the Filser toxicoki-
netic model was used for back-extrapolation
(24). For the 96 women with nondetectable
values, a serum TCDD level equal to one-
half the detection limit was assigned (25).
For the lipid-adjusted study median serum
sample weight of 0.65 g, the median limit of
detection was 18.8 ppt. 
Statistical analyses. We analyzed serum
TCDD both as a continuous (log10 TCDD)
and as a categorical variable. Serum TCDD
was categorized as < 20.0 ppt, 20.1–44 ppt,
44.1–100 ppt, and > 100 ppt. The lowest
cut point was set at 20 ppt (body burden ~4
ng/kg) because the median value was
between 15 and 20 ppt for 11 pooled serum
samples collected from women residing in an
unexposed zone, non-ABR, at the time of
the explosion (26). The highest cut point
was set at 100 ppt (body burden ~20 ng/kg)
because previous studies in Seveso reported
an effect of TCDD at about this level
(27,28). The middle cutpoint was set at 44
ppt (body burden ~8.8 ng/kg) to make the
middle groups comparable in size.
Statistical analyses were performed using
STATA 7.0 (29). We used Cox proportional
hazards modeling for the main analysis. The
response variable was age at breast cancer
diagnosis or age at interview for non-cases,
and each subject entered the analysis at her
age on the explosion date, 10 July 1976. We
report the measure of effect as the hazard
ratio (HR) and 95% CI. We examined the
effect of potential confounders and effect
modiﬁers identiﬁed in the breast cancer liter-
ature (30,31). Confounders included gravid-
ity, parity, age at ﬁrst pregnancy, age at last
pregnancy, lactation, family history of breast
cancer, age at menarche, current body mass
index, oral contraceptive use, menarcheal sta-
tus at explosion, menopause status at diagno-
sis, weight, height, smoking, and alcohol
consumption. Because of the small number
of cases, these variables were entered into the
models one at a time.
Results
Table 1 presents the distribution of selected
characteristics of the SWHS cohort at the
time of interview (1996–1998). On 10 July
1976, 232 women (24%) were younger than
10 years old, and 283 (29%) were premenar-
cheal. The average age of the cohort at inter-
view was 40.8 (SD = 11.7) years, and 264
women (27%) were nulliparous. The mean
age at first pregnancy for the 717 parous
women was 24.2 years, and 626 (87%) had
ever lactated. Seventy-five women (8%)
reported a family history of breast cancer.
A total of 21 women (2.1%) in the
SWHS cohort reported that they had been
diagnosed with cancer. Fifteen women (1.5%)
had been diagnosed with breast cancer
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Table 1. Characteristics of breast cancer cases
(n = 15) and full SWHS cohort (n = 981), Italy,
1996–1998.
No. No.  full
Characteristic cases cohort (%)
Age at explosion (years) 
0–10 0 232 (23.6)
11–20 2 279 (28.4)
21–30 3 241 (24.6)
31–40 10 229 (23.3)
Menarche status at explosiona
Premenarche 1 283 (28.8)
Postmenarche 14 697 (71.0)
Age at interview (years)
20–29 0 191 (19.5)
30–39 2 284 (29.0)
40–49 2 244 (24.9)
≥ 50 11 262 (26.7)
Parity 
03 264 (26.9)
1–2 8 551 (56.2)
≥ 34 166 (16.9)
Age at ﬁrst full-term pregnancy (years)
< 20 1 117 (11.9)
20–25 4 357 (36.4)
> 25 7 243 (24.8)
Nulliparous 3 264 (26.9)
Lactation
Never 2 91 (12.7)
Ever 10 626 (87.3)
Family history of breast cancera
No 13 900 (91.8)
Yes 2 75 (7.6)
Oral contraceptive use
Never 9 456 (46.5)
Former 6 377 (38.4)
Current 0 148 (15.1)
Cigarette smoking
Never 10 638 (65.0)
Former 4 141 (14.4)
Current 1 202 (20.6)
aNumbers do not add to 100% because of missing data.
Table 2. Characteristics of breast cancer cases, SWHS, Italy.
Breast Serum Age at Age at Years from Estrogen Progesterone
cancer TCDD exposure diagnosis exposure Pathologic Menopausal receptor receptor
cases (ppt) (years) (years) to diagnosisa conﬁrmation at diagnosis status status
1 13.1 31 52 21 Yes No + +
2 27.2 23 34 11 Yes No
3 40.1 35 48 13 Yes Yes
4 47.3 30 41 11 Yes No
5 49.4 34 51 18 Yes No – +
6 55.8 38 46 8 Yes No + +
7 57.2 36 48 12 No Yes + +
8 71.8 14 33 19 Yes No + +
9 83.6 36 57 20 Yes Yes
10 85.2 39 49 11 Yes No
11 191.0 21 41 20 Yes No + +
12 200.0 37 57 20 No Yes
13 220.0 14 31 18 Yes No + +
14 1160.0 32 42 9 Yes Yes
15 1960.0 31 48 17 Yes Yes
aRounded to nearest year. [International Classification of Diseases, 9th
Revision (ICD-9), 174.8, 174.9] (32). Other
diagnosed cancers and their respective individ-
ual serum TCDD levels included thyroid (n =
3; ICD-9, 193.8, 193.9; serum TCDD levels:
6.6, 106.0, 476.0 ppt); kidney (ICD-9, 172.9;
serum TCDD level: 30.0 ppt); melanoma
(ICD-9, 189.9; serum TCDD level: 20.6
ppt); and nonspeciﬁed (ICD-9, 195.5; serum
TCDD level: 174.0 ppt). Because of the small
numbers of cases, we only examined the rela-
tion of serum TCDD levels to breast cancer
and all cancers combined.
Table 2 presents selected characteristics
of the 15 breast cancer cases. Of the 15 cases,
13 (87%) were conﬁrmed by pathology; the
other two (13%) were conﬁrmed by surgery
report alone. The serum TCDD levels of
women with breast cancer ranged from 13.1
to 1,960.0 ppt (median = 71.8 ppt). The
average age of women with breast cancer on
the explosion date was 30.1 years, with a
range of 14–39 years. The average age at
diagnosis was 45.2 years, with a range of
31–57 years. Breast cancer was diagnosed, on
average, 15.2 years after the explosion, with
the shortest period being 8 years. At diagno-
sis, nine (60%) women were premenopausal
and six (40%) were postmenopausal. For the
seven women for whom receptor status of
tumors was available, six (87%) were estro-
gen-receptor positive and seven (100%) were
progesterone-receptor positive. 
The cumulative distribution of serum
TCDD levels is presented in Figure 1 for all
women in the cohort and for only women
with breast cancer. The median serum
TCDD level for women with breast cancer
(median = 71.8 ppt, interquartile range
47.3–200.0) was greater than for women
without breast cancer (median = 55.1 ppt,
interquartile range 27.8–153.0). Although
the total number of cases is small, the
TCDD levels for women with breast cancer
appear to be shifted to the right at the low
end of the cumulative distribution. At the
high end of the distribution the shift is not
apparent. 
In single-covariate Cox models, breast can-
cer risk was positively associated with younger
age of menarche, lower gravidity, lower parity,
never lactating, older age at ﬁrst pregnancy,
and family history of breast cancer. There was
no association of breast cancer risk with age at
explosion or menarche status (pre- or post-)
on the date of the explosion (data not shown). 
Table 3 presents the results of Cox pro-
portional hazards modeling for the associa-
tion between lipid-adjusted serum TCDD
level and breast cancer risk. When TCDD
was included as a continuous variable (log10
TCDD), the HR was signiﬁcantly increased
to 2.1 (95% CI, 1.0–4.6). That is, for a 10-
fold increase in TCDD (e.g., from 10 to 100
ppt), a doubling of the hazard rate is
predicted. The test for trend with continuous
log10 TCDD was signiﬁcant (p = 0.05). After
adjusting for single covariates, no single vari-
able was found to confound (i.e., change the
TCDD parameter estimate by more than
10%) or to modify the TCDD–breast cancer
association (data not shown). If the two cases
that were diagnosed by surgery report alone
were excluded from the analysis, the result
was similar (HR = 2.1, 95% CI, 0.9–4.8). 
When TCDD was considered as a cate-
gorical variable, there was some evidence of a
dose–response trend, but it was not statisti-
cally signiﬁcant (χ2 = 3.3, df = 1, p = 0.07).
Compared to the lowest exposure group (< 20
ppt), the HR (95% CI) for the three dose
groups, 20.1–44 ppt, 44.1–100 ppt, and >
100 ppt, were 1.0 (0.1–10.8), 4.5 (0.6–36.8),
and 3.3 (0.4–28.0), respectively. After adjust-
ment for single covariates, including parity,
the results were unchanged. 
We also conducted Cox proportional
hazards modeling for the association between
serum TCDD level and risk for all cancers.
The HR (95% CI) for all cancers associated
with a 10-fold increase in exposure (log10
TCDD) was 1.7 (0.9–3.4). When TCDD
was categorized, there was some evidence of a
dose response, but it was not statistically sig-
nificant (χ2 = 2.9, df = 1, p = 0.09).
Compared to the lowest exposure group
(< 20 ppt), the HR (95% CI) for the three
higher dose groups, 20.1–44 ppt, 44.1–100
ppt, and > 100 ppt, were 1.0 (0.2–5.5), 2.2
(0.5–10.8), and 2.5 (0.5–11.8), respectively.
Discussion
We observed a statistically significant, dose
response–increased risk for breast cancer
incidence with individual serum TCDD
level among women in the Seveso Women’s
Health Study. We found more than a 2-fold
increase in the hazard rate associated with a
10-fold increase in serum TCDD. This
result should be considered an early ﬁnding
because the SWHS cohort is relatively
young, with an average age at interview of
40.8 years. Breast cancer incidence increases
steadily with age, with the most rapid
increase between ages 40 and 55 years (30).
Moreover, the youngest women in the
SWHS cohort were, in general, the most
highly exposed (19). Of women who were
20–30 years of age at interview, 68% had
serum TCDD levels > 100 ppt. Many of
these women may not have had sufficient
time for the effects of TCDD, if any, to
become clinically manifest. Thus, it will be
important to continue to follow the SWHS
cohort. 
The major limitation of our study is the
small number of breast cancer cases.
However, previous studies of occupational
cohorts of TCDD-exposed women have had
similar numbers, ranging from 9 to 23 cases,
and have reported similar levels of risk (RR
~1.8–2.8) (6–8). These studies classified
exposure based on job history, company pro-
duction records, and, for a subset of workers,
TCDD in serum or adipose measured many
years after last exposure. 
The results of the SWHS are consistent
with those from the 20-year mortality study
of the larger Seveso population, which
reported a nonsignificant increased risk for
mortality from breast cancer among women
who were 54 years old or younger at death
(18). However, the observations of the mor-
tality study and SWHS are likely indepen-
dent. The SWHS cohort included women
who were infants to 40 years old in 1976,
while the larger Seveso cohort included
women who were 20–74 years old. In addi-
tion, we included incident cases diagnosed
between 1976 and 1997, but not deaths (18).
Of the 33 women who did not participate in
the SWHS because they were dead or too ill,
three had had breast cancer (deceased). 
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Figure 1. Cumulative distribution of 1976 serum
TCDD levels for breast cancer cases (n = 15) versus
full cohort (n = 981), SWHS, Italy.
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Table 3. Results of Cox proportional hazards model for association between lipid-adjusted serum TCDD
levels and female breast cancer risk, SWHS, Italy.
Exposure Cases/total Crude hazard ratio (95% CI) p-Value
Log10 TCDDa (ppt) 15/981 2.1 (1.0–4.6) 0.05
TCDD (ppt)
< 20 1/156 1.0 
20.1–44 2/241 1.0 (0.1–10.8)
44.1–100 7/249 4.5 (0.6–36.8)
> 100 5/335 3.3 (0.4–28.0) 0.07b
aHazard ratio for 10-fold increase in serum TCDD concentration. bTest for trend.The results of the SWHS are not consis-
tent with the most recent cancer incidence
study of the larger Seveso population (13).
However, follow-up for that study was only
through 1986, and most breast cancer cases
in SWHS were diagnosed since then (13 of
15 cases). Using age-specific breast cancer
rates for the region (1988–1992) (33), the
expected number of cases is 11, whereas we
report 15; the overall standardized incidence
ratio for the 981 women is 1.36.
An advantage of the SWHS is that we
were able to examine the relationship
between serum TCDD concentration and
breast cancer incidence, thus eliminating
potential bias associated with disease survival.
In addition, we were able to collect informa-
tion during the interview, allowing consider-
ation of potential confounding by known
risk factors in the analysis. Finally, we were
able to measure individual serum TCDD
concentrations near the time of exposure,
thus minimizing exposure misclassiﬁcation.
In both animal and human studies,
TCDD has been shown to be a multisite
carcinogen (5). TCDD has been shown to
induce antiestrogenic responses in rodent
uterus and human breast cancer cells in cul-
ture (34,35). However, the ﬁnding of a sig-
niﬁcant positive association between TCDD
exposure and breast cancer risk is supported
by recent animal studies (36–39). These
studies suggest that TCDD can modulate
the risk of mammary cancer in different
ways depending on the developmental stage
at exposure. Postnatal TCDD exposure in
female rats has been shown to suppress
mammary gland development (36) and to
inhibit progression of chemically induced
mammary carcinoma (37). In utero and lac-
tational TCDD exposure, however, has been
shown to alter mammary gland differentia-
tion by increasing the number of terminal
end buds (38,39) and rendering the animals
more susceptible to chemically induced car-
cinogenesis (38). It is not known whether
prenatal or postnatal TCDD exposure differ-
entially alters mammary gland differentiation
in humans (38,39). The animal findings,
however, suggest that we may not yet have
observed the effect of TCDD on the most
sensitive individuals in SWHS, those who
were exposed in utero or before menarche at
the time of the explosion.
In summary, we have shown that indi-
vidual serum TCDD measurements are sig-
niﬁcantly related to breast cancer incidence
among women in the SWHS cohort. This
result should be considered an early ﬁnding
because the number of cases is small and the
cohort is relatively young. Continued fol-
low-up of the SWHS cohort will help shed
light on the possible role of TCDD in the
pathogenesis of breast cancer. 
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